Latest News
PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML
22 April 2026 - Biotherapeutics company PureTech Health plc reported on Wednesday that its founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome (MDS) and acute my...
Natera showcases Prospera transplant data across 17 presentations at ISHLT 2026
22 April 2026 -

Precision medicine company Natera Inc (NASDAQ: NTRA) on Wednesday announced the presentation of new clinical evidence supporting its Prospera test across 17 abstracts, including six ...

Johnson & Johnson secures EU approval for ETHICON 4000 surgical stapler
22 April 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Wednesday that it has received European CE Mark approval for the ETHICON 4000 Stapler, designed to deliver consistent staple line integrity across varying tissu...
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for patients aged si...
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
22 April 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) announced on Wednesday that it has appointed US-based research and investor engagement firm Water Tower Research LLC to enhance its understanding of the US market, refine...